Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Common Equity (2016 - 2025)

STRATA Skin Sciences (SSKN) has disclosed Common Equity for 14 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 41.51% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, down 41.51% year-over-year, with the annual reading at $2.9 million for FY2025, 41.51% down from the prior year.
  • Common Equity hit $2.9 million in Q4 2025 for STRATA Skin Sciences, up from $1.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $26.2 million in Q3 2021 to a low of $532000.0 in Q2 2025.
  • Historically, Common Equity has averaged $14.9 million across 5 years, with a median of $16.6 million in 2023.
  • Biggest five-year swings in Common Equity: grew 0.99% in 2021 and later tumbled 94.4% in 2025.
  • Year by year, Common Equity stood at $25.4 million in 2021, then fell by 14.1% to $21.8 million in 2022, then tumbled by 41.88% to $12.7 million in 2023, then tumbled by 60.81% to $5.0 million in 2024, then plummeted by 41.51% to $2.9 million in 2025.
  • Business Quant data shows Common Equity for SSKN at $2.9 million in Q4 2025, $1.3 million in Q3 2025, and $532000.0 in Q2 2025.